Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Akkermansia muciniphila & Immune Checkpoint Inhibitors (ICIs)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Administration of a strain of A. muciniphila improved the anti-tumor activity following treatment with anti-PD1 agents in both germ-free mice transplanted with stool from non-responders and in mice pre-exposed to antibiotics
Cani et al. 2022 Nat Rev Gastroenterol Hepatol 19(10): 625-637

A. muciniphila is a promising candidate to enhance the [clinical response](brain://ChTLBVJqRkiQRo6o…

Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis
Ansaldo et al. 2019 Science 364: 1179-1184
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms
Cani et al. 2022 Nat Rev Gastroenterol Hepatol 19(10): 625-637
Review
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy et al. 2018 Science 359: 91–97
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
Derosa et al. 2022 Nat. Med. 28: 315-324
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Depommier et al. 2019 Nat Med. 25(7): 1096-1103
Too much water drowned the miller: Akkermansia determines immunotherapy responses
Li & McAllister 2022 Cell Rep Med 3(5): 100642

7/2/2026